The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.

Merck dazzled with Phase 3 trial results for its PAH drug WINREVAIR, but the market responded with a collective shrug, ...

Communication between health-care professionals and individuals with cancer regarding the effects of treatment on sexual ...

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...

Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...

Discover why Immutep's Eftilagimod Alpha shows promise in NSCLC and HNSCC trials, but cautious investment is advised. Explore more details here.

Data suggest that SC pembrolizumab is non-inferior to IV pembrolizumab in patients with newly diagnosed, advanced NSCLC.

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...

The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...